eLife-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1198682, encodeId=69a31198682af, content=投稿命中率:5.0 偏重的研究方向：cell biology;微生物 经验分享：以后IF这种评价标准意义不大了，像elife这种完全不会主动去操作影响因子的杂志在中国认可度一定会越来越高，随便给大家推荐一个网站 https://www.resurchify.com/ranking 去这里面查杂志的好坏参考价值远比看IF来的靠谱，比如国产神刊之一的STTT排名是357，IF同样是8分的CDD排名是922，10分神刊JECCR排名是749，而elife排名是219, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=558, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f4e1713538, createdName=alexib, createdTime=Wed Mar 02 12:30:46 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2203519, encodeId=83a2220351957, content=偏重的研究方向：乳腺癌 经验分享： Stage Start Date Under editorial assessment 7th May 24 Initial quality checks complete 7th May 24 Staff checks pending 4th May 24 Manuscript submitted 4th May 24 Submission incomplete 3rd May 24 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Wed May 08 19:51:51 CST 2024, time=2024-05-08, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=580680, encodeId=1968580680ed, content=请问这个杂志拒稿快么？临近毕业还是想试一下高分，怕耽误太久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16365175013, createdName=146e4e40m72暂无昵称, createdTime=Fri Nov 29 00:00:00 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191264, encodeId=91d5119126433, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：Biomarker 经验分享：目前杂志只接受预印本。如果初审通过，必须先在预印本发表。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d03856469, createdName=bigOne, createdTime=Tue Feb 08 23:15:05 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861997, encodeId=706d86199e5b, content=审稿速度:1.0 经验分享：国际顶级期刊，审稿专家和编辑都非常严谨敬业，投稿难度挺大的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ce15414064, createdName=ms4608271349787965, createdTime=Tue Jun 16 23:01:04 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555417, encodeId=a3d255541e2e, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：个人感觉 elife 这个杂志投稿难度相当大，我曾经在这个杂志上栽过一次跟头，我们实验室做的关于RLKs参与植物抗逆的研究，投稿 elife 不到二周拒稿，最终文章被另一个高 IF 杂志 molecular cell 接收。 个人感觉说 elife 投稿容易的纯粹是扯淡！在生物学期刊里，molecular cell 的投稿难度相当大，至少远远难于 nature communications 、cell research 之流，而从我们实验室投稿经历来看， elife 投稿难度高于 molecular cell ，因此不难推测出 elife 投稿难度，绝对远远难于 nature communications 、cell research 之流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=664, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb651930132, createdName=storyhare, createdTime=Thu Apr 26 10:39:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2208556, encodeId=da172208556d8, content=偏重的研究方向：基础研究;口腔;生信 经验分享：请问投稿过程中under pending review阶段，稿件可以要求撤回修改吗，手稿提交出现错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:13:27 CST 2024, time=16小时前, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2203680, encodeId=ee3f22036805a, content=5月3号投出去，不知道编辑手里要多久，头大。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Thu May 09 15:15:33 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=575383, encodeId=adde5e538303, content=2019年8月15日投的稿，已经12天了，状态还是subbmitted，有没有大神遇到到这种情况，不是说elife审稿速度快吗？好着急啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58425127264, createdName=小高兴, createdTime=Mon Aug 26 22:49:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240235, encodeId=42021240235a0, content=2022未来科学奖的李文辉发的就是这个，这个杂志基本可以看成是open acess的PNAS，水平和投稿难度和PNAS基本差不多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7b18287601, createdName=ms7000000077155394, createdTime=Mon Aug 22 09:37:49 CST 2022, time=2022-08-22, status=1, ipAttribution=)]

2022-03-02 alexib

投稿命中率:5.0
偏重的研究方向：cell biology;微生物
经验分享：以后IF这种评价标准意义不大了，像elife这种完全不会主动去操作影响因子的杂志在中国认可度一定会越来越高，随便给大家推荐一个网站 https://www.resurchify.com/ranking 去这里面查杂志的好坏参考价值远比看IF来的靠谱，比如国产神刊之一的STTT排名是357，IF同样是8分的CDD排名是922，10分神刊JECCR排名是749，而elife排名是219

558 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1198682, encodeId=69a31198682af, content=投稿命中率:5.0 偏重的研究方向：cell biology;微生物 经验分享：以后IF这种评价标准意义不大了，像elife这种完全不会主动去操作影响因子的杂志在中国认可度一定会越来越高，随便给大家推荐一个网站 https://www.resurchify.com/ranking 去这里面查杂志的好坏参考价值远比看IF来的靠谱，比如国产神刊之一的STTT排名是357，IF同样是8分的CDD排名是922，10分神刊JECCR排名是749，而elife排名是219, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=558, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f4e1713538, createdName=alexib, createdTime=Wed Mar 02 12:30:46 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2203519, encodeId=83a2220351957, content=偏重的研究方向：乳腺癌 经验分享： Stage Start Date Under editorial assessment 7th May 24 Initial quality checks complete 7th May 24 Staff checks pending 4th May 24 Manuscript submitted 4th May 24 Submission incomplete 3rd May 24 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Wed May 08 19:51:51 CST 2024, time=2024-05-08, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=580680, encodeId=1968580680ed, content=请问这个杂志拒稿快么？临近毕业还是想试一下高分，怕耽误太久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16365175013, createdName=146e4e40m72暂无昵称, createdTime=Fri Nov 29 00:00:00 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191264, encodeId=91d5119126433, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：Biomarker 经验分享：目前杂志只接受预印本。如果初审通过，必须先在预印本发表。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d03856469, createdName=bigOne, createdTime=Tue Feb 08 23:15:05 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861997, encodeId=706d86199e5b, content=审稿速度:1.0 经验分享：国际顶级期刊，审稿专家和编辑都非常严谨敬业，投稿难度挺大的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ce15414064, createdName=ms4608271349787965, createdTime=Tue Jun 16 23:01:04 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555417, encodeId=a3d255541e2e, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：个人感觉 elife 这个杂志投稿难度相当大，我曾经在这个杂志上栽过一次跟头，我们实验室做的关于RLKs参与植物抗逆的研究，投稿 elife 不到二周拒稿，最终文章被另一个高 IF 杂志 molecular cell 接收。 个人感觉说 elife 投稿容易的纯粹是扯淡！在生物学期刊里，molecular cell 的投稿难度相当大，至少远远难于 nature communications 、cell research 之流，而从我们实验室投稿经历来看， elife 投稿难度高于 molecular cell ，因此不难推测出 elife 投稿难度，绝对远远难于 nature communications 、cell research 之流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=664, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb651930132, createdName=storyhare, createdTime=Thu Apr 26 10:39:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2208556, encodeId=da172208556d8, content=偏重的研究方向：基础研究;口腔;生信 经验分享：请问投稿过程中under pending review阶段，稿件可以要求撤回修改吗，手稿提交出现错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:13:27 CST 2024, time=16小时前, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2203680, encodeId=ee3f22036805a, content=5月3号投出去，不知道编辑手里要多久，头大。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Thu May 09 15:15:33 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=575383, encodeId=adde5e538303, content=2019年8月15日投的稿，已经12天了，状态还是subbmitted，有没有大神遇到到这种情况，不是说elife审稿速度快吗？好着急啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58425127264, createdName=小高兴, createdTime=Mon Aug 26 22:49:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240235, encodeId=42021240235a0, content=2022未来科学奖的李文辉发的就是这个，这个杂志基本可以看成是open acess的PNAS，水平和投稿难度和PNAS基本差不多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7b18287601, createdName=ms7000000077155394, createdTime=Mon Aug 22 09:37:49 CST 2022, time=2022-08-22, status=1, ipAttribution=)]

2024-05-08 1487e742m42(暂无昵称) 来自内蒙古

偏重的研究方向：乳腺癌
经验分享： Stage Start Date
Under editorial assessment 7th May 24
Initial quality checks complete 7th May 24
Staff checks pending 4th May 24
Manuscript submitted 4th May 24
Submission incomplete 3rd May 24

11 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1198682, encodeId=69a31198682af, content=投稿命中率:5.0 偏重的研究方向：cell biology;微生物 经验分享：以后IF这种评价标准意义不大了，像elife这种完全不会主动去操作影响因子的杂志在中国认可度一定会越来越高，随便给大家推荐一个网站 https://www.resurchify.com/ranking 去这里面查杂志的好坏参考价值远比看IF来的靠谱，比如国产神刊之一的STTT排名是357，IF同样是8分的CDD排名是922，10分神刊JECCR排名是749，而elife排名是219, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=558, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f4e1713538, createdName=alexib, createdTime=Wed Mar 02 12:30:46 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2203519, encodeId=83a2220351957, content=偏重的研究方向：乳腺癌 经验分享： Stage Start Date Under editorial assessment 7th May 24 Initial quality checks complete 7th May 24 Staff checks pending 4th May 24 Manuscript submitted 4th May 24 Submission incomplete 3rd May 24 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Wed May 08 19:51:51 CST 2024, time=2024-05-08, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=580680, encodeId=1968580680ed, content=请问这个杂志拒稿快么？临近毕业还是想试一下高分，怕耽误太久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16365175013, createdName=146e4e40m72暂无昵称, createdTime=Fri Nov 29 00:00:00 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191264, encodeId=91d5119126433, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：Biomarker 经验分享：目前杂志只接受预印本。如果初审通过，必须先在预印本发表。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d03856469, createdName=bigOne, createdTime=Tue Feb 08 23:15:05 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861997, encodeId=706d86199e5b, content=审稿速度:1.0 经验分享：国际顶级期刊，审稿专家和编辑都非常严谨敬业，投稿难度挺大的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ce15414064, createdName=ms4608271349787965, createdTime=Tue Jun 16 23:01:04 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555417, encodeId=a3d255541e2e, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：个人感觉 elife 这个杂志投稿难度相当大，我曾经在这个杂志上栽过一次跟头，我们实验室做的关于RLKs参与植物抗逆的研究，投稿 elife 不到二周拒稿，最终文章被另一个高 IF 杂志 molecular cell 接收。 个人感觉说 elife 投稿容易的纯粹是扯淡！在生物学期刊里，molecular cell 的投稿难度相当大，至少远远难于 nature communications 、cell research 之流，而从我们实验室投稿经历来看， elife 投稿难度高于 molecular cell ，因此不难推测出 elife 投稿难度，绝对远远难于 nature communications 、cell research 之流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=664, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb651930132, createdName=storyhare, createdTime=Thu Apr 26 10:39:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2208556, encodeId=da172208556d8, content=偏重的研究方向：基础研究;口腔;生信 经验分享：请问投稿过程中under pending review阶段，稿件可以要求撤回修改吗，手稿提交出现错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:13:27 CST 2024, time=16小时前, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2203680, encodeId=ee3f22036805a, content=5月3号投出去，不知道编辑手里要多久，头大。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Thu May 09 15:15:33 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=575383, encodeId=adde5e538303, content=2019年8月15日投的稿，已经12天了，状态还是subbmitted，有没有大神遇到到这种情况，不是说elife审稿速度快吗？好着急啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58425127264, createdName=小高兴, createdTime=Mon Aug 26 22:49:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240235, encodeId=42021240235a0, content=2022未来科学奖的李文辉发的就是这个，这个杂志基本可以看成是open acess的PNAS，水平和投稿难度和PNAS基本差不多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7b18287601, createdName=ms7000000077155394, createdTime=Mon Aug 22 09:37:49 CST 2022, time=2022-08-22, status=1, ipAttribution=)]

2019-11-29 146e4e40m72暂无昵称

请问这个杂志拒稿快么？临近毕业还是想试一下高分，怕耽误太久

190 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1198682, encodeId=69a31198682af, content=投稿命中率:5.0 偏重的研究方向：cell biology;微生物 经验分享：以后IF这种评价标准意义不大了，像elife这种完全不会主动去操作影响因子的杂志在中国认可度一定会越来越高，随便给大家推荐一个网站 https://www.resurchify.com/ranking 去这里面查杂志的好坏参考价值远比看IF来的靠谱，比如国产神刊之一的STTT排名是357，IF同样是8分的CDD排名是922，10分神刊JECCR排名是749，而elife排名是219, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=558, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f4e1713538, createdName=alexib, createdTime=Wed Mar 02 12:30:46 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2203519, encodeId=83a2220351957, content=偏重的研究方向：乳腺癌 经验分享： Stage Start Date Under editorial assessment 7th May 24 Initial quality checks complete 7th May 24 Staff checks pending 4th May 24 Manuscript submitted 4th May 24 Submission incomplete 3rd May 24 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Wed May 08 19:51:51 CST 2024, time=2024-05-08, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=580680, encodeId=1968580680ed, content=请问这个杂志拒稿快么？临近毕业还是想试一下高分，怕耽误太久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16365175013, createdName=146e4e40m72暂无昵称, createdTime=Fri Nov 29 00:00:00 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191264, encodeId=91d5119126433, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：Biomarker 经验分享：目前杂志只接受预印本。如果初审通过，必须先在预印本发表。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d03856469, createdName=bigOne, createdTime=Tue Feb 08 23:15:05 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861997, encodeId=706d86199e5b, content=审稿速度:1.0 经验分享：国际顶级期刊，审稿专家和编辑都非常严谨敬业，投稿难度挺大的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ce15414064, createdName=ms4608271349787965, createdTime=Tue Jun 16 23:01:04 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555417, encodeId=a3d255541e2e, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：个人感觉 elife 这个杂志投稿难度相当大，我曾经在这个杂志上栽过一次跟头，我们实验室做的关于RLKs参与植物抗逆的研究，投稿 elife 不到二周拒稿，最终文章被另一个高 IF 杂志 molecular cell 接收。 个人感觉说 elife 投稿容易的纯粹是扯淡！在生物学期刊里，molecular cell 的投稿难度相当大，至少远远难于 nature communications 、cell research 之流，而从我们实验室投稿经历来看， elife 投稿难度高于 molecular cell ，因此不难推测出 elife 投稿难度，绝对远远难于 nature communications 、cell research 之流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=664, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb651930132, createdName=storyhare, createdTime=Thu Apr 26 10:39:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2208556, encodeId=da172208556d8, content=偏重的研究方向：基础研究;口腔;生信 经验分享：请问投稿过程中under pending review阶段，稿件可以要求撤回修改吗，手稿提交出现错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:13:27 CST 2024, time=16小时前, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2203680, encodeId=ee3f22036805a, content=5月3号投出去，不知道编辑手里要多久，头大。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Thu May 09 15:15:33 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=575383, encodeId=adde5e538303, content=2019年8月15日投的稿，已经12天了，状态还是subbmitted，有没有大神遇到到这种情况，不是说elife审稿速度快吗？好着急啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58425127264, createdName=小高兴, createdTime=Mon Aug 26 22:49:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240235, encodeId=42021240235a0, content=2022未来科学奖的李文辉发的就是这个，这个杂志基本可以看成是open acess的PNAS，水平和投稿难度和PNAS基本差不多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7b18287601, createdName=ms7000000077155394, createdTime=Mon Aug 22 09:37:49 CST 2022, time=2022-08-22, status=1, ipAttribution=)]

2022-02-08 bigOne

审稿速度:2.0 | 投稿命中率:5.0
偏重的研究方向：Biomarker
经验分享：目前杂志只接受预印本。如果初审通过，必须先在预印本发表。

89 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1198682, encodeId=69a31198682af, content=投稿命中率:5.0 偏重的研究方向：cell biology;微生物 经验分享：以后IF这种评价标准意义不大了，像elife这种完全不会主动去操作影响因子的杂志在中国认可度一定会越来越高，随便给大家推荐一个网站 https://www.resurchify.com/ranking 去这里面查杂志的好坏参考价值远比看IF来的靠谱，比如国产神刊之一的STTT排名是357，IF同样是8分的CDD排名是922，10分神刊JECCR排名是749，而elife排名是219, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=558, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f4e1713538, createdName=alexib, createdTime=Wed Mar 02 12:30:46 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2203519, encodeId=83a2220351957, content=偏重的研究方向：乳腺癌 经验分享： Stage Start Date Under editorial assessment 7th May 24 Initial quality checks complete 7th May 24 Staff checks pending 4th May 24 Manuscript submitted 4th May 24 Submission incomplete 3rd May 24 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Wed May 08 19:51:51 CST 2024, time=2024-05-08, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=580680, encodeId=1968580680ed, content=请问这个杂志拒稿快么？临近毕业还是想试一下高分，怕耽误太久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16365175013, createdName=146e4e40m72暂无昵称, createdTime=Fri Nov 29 00:00:00 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191264, encodeId=91d5119126433, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：Biomarker 经验分享：目前杂志只接受预印本。如果初审通过，必须先在预印本发表。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d03856469, createdName=bigOne, createdTime=Tue Feb 08 23:15:05 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861997, encodeId=706d86199e5b, content=审稿速度:1.0 经验分享：国际顶级期刊，审稿专家和编辑都非常严谨敬业，投稿难度挺大的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ce15414064, createdName=ms4608271349787965, createdTime=Tue Jun 16 23:01:04 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555417, encodeId=a3d255541e2e, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：个人感觉 elife 这个杂志投稿难度相当大，我曾经在这个杂志上栽过一次跟头，我们实验室做的关于RLKs参与植物抗逆的研究，投稿 elife 不到二周拒稿，最终文章被另一个高 IF 杂志 molecular cell 接收。 个人感觉说 elife 投稿容易的纯粹是扯淡！在生物学期刊里，molecular cell 的投稿难度相当大，至少远远难于 nature communications 、cell research 之流，而从我们实验室投稿经历来看， elife 投稿难度高于 molecular cell ，因此不难推测出 elife 投稿难度，绝对远远难于 nature communications 、cell research 之流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=664, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb651930132, createdName=storyhare, createdTime=Thu Apr 26 10:39:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2208556, encodeId=da172208556d8, content=偏重的研究方向：基础研究;口腔;生信 经验分享：请问投稿过程中under pending review阶段，稿件可以要求撤回修改吗，手稿提交出现错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:13:27 CST 2024, time=16小时前, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2203680, encodeId=ee3f22036805a, content=5月3号投出去，不知道编辑手里要多久，头大。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Thu May 09 15:15:33 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=575383, encodeId=adde5e538303, content=2019年8月15日投的稿，已经12天了，状态还是subbmitted，有没有大神遇到到这种情况，不是说elife审稿速度快吗？好着急啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58425127264, createdName=小高兴, createdTime=Mon Aug 26 22:49:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240235, encodeId=42021240235a0, content=2022未来科学奖的李文辉发的就是这个，这个杂志基本可以看成是open acess的PNAS，水平和投稿难度和PNAS基本差不多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7b18287601, createdName=ms7000000077155394, createdTime=Mon Aug 22 09:37:49 CST 2022, time=2022-08-22, status=1, ipAttribution=)]

2020-06-16 ms4608271349787965

审稿速度:1.0
经验分享：国际顶级期刊，审稿专家和编辑都非常严谨敬业，投稿难度挺大的

436 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1198682, encodeId=69a31198682af, content=投稿命中率:5.0 偏重的研究方向：cell biology;微生物 经验分享：以后IF这种评价标准意义不大了，像elife这种完全不会主动去操作影响因子的杂志在中国认可度一定会越来越高，随便给大家推荐一个网站 https://www.resurchify.com/ranking 去这里面查杂志的好坏参考价值远比看IF来的靠谱，比如国产神刊之一的STTT排名是357，IF同样是8分的CDD排名是922，10分神刊JECCR排名是749，而elife排名是219, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=558, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f4e1713538, createdName=alexib, createdTime=Wed Mar 02 12:30:46 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2203519, encodeId=83a2220351957, content=偏重的研究方向：乳腺癌 经验分享： Stage Start Date Under editorial assessment 7th May 24 Initial quality checks complete 7th May 24 Staff checks pending 4th May 24 Manuscript submitted 4th May 24 Submission incomplete 3rd May 24 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Wed May 08 19:51:51 CST 2024, time=2024-05-08, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=580680, encodeId=1968580680ed, content=请问这个杂志拒稿快么？临近毕业还是想试一下高分，怕耽误太久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16365175013, createdName=146e4e40m72暂无昵称, createdTime=Fri Nov 29 00:00:00 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191264, encodeId=91d5119126433, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：Biomarker 经验分享：目前杂志只接受预印本。如果初审通过，必须先在预印本发表。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d03856469, createdName=bigOne, createdTime=Tue Feb 08 23:15:05 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861997, encodeId=706d86199e5b, content=审稿速度:1.0 经验分享：国际顶级期刊，审稿专家和编辑都非常严谨敬业，投稿难度挺大的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ce15414064, createdName=ms4608271349787965, createdTime=Tue Jun 16 23:01:04 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555417, encodeId=a3d255541e2e, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：个人感觉 elife 这个杂志投稿难度相当大，我曾经在这个杂志上栽过一次跟头，我们实验室做的关于RLKs参与植物抗逆的研究，投稿 elife 不到二周拒稿，最终文章被另一个高 IF 杂志 molecular cell 接收。 个人感觉说 elife 投稿容易的纯粹是扯淡！在生物学期刊里，molecular cell 的投稿难度相当大，至少远远难于 nature communications 、cell research 之流，而从我们实验室投稿经历来看， elife 投稿难度高于 molecular cell ，因此不难推测出 elife 投稿难度，绝对远远难于 nature communications 、cell research 之流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=664, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb651930132, createdName=storyhare, createdTime=Thu Apr 26 10:39:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2208556, encodeId=da172208556d8, content=偏重的研究方向：基础研究;口腔;生信 经验分享：请问投稿过程中under pending review阶段，稿件可以要求撤回修改吗，手稿提交出现错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:13:27 CST 2024, time=16小时前, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2203680, encodeId=ee3f22036805a, content=5月3号投出去，不知道编辑手里要多久，头大。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Thu May 09 15:15:33 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=575383, encodeId=adde5e538303, content=2019年8月15日投的稿，已经12天了，状态还是subbmitted，有没有大神遇到到这种情况，不是说elife审稿速度快吗？好着急啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58425127264, createdName=小高兴, createdTime=Mon Aug 26 22:49:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240235, encodeId=42021240235a0, content=2022未来科学奖的李文辉发的就是这个，这个杂志基本可以看成是open acess的PNAS，水平和投稿难度和PNAS基本差不多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7b18287601, createdName=ms7000000077155394, createdTime=Mon Aug 22 09:37:49 CST 2022, time=2022-08-22, status=1, ipAttribution=)]

2018-04-26 storyhare

审稿速度:1.0 | 投稿命中率:5.0
经验分享：个人感觉 elife 这个杂志投稿难度相当大，我曾经在这个杂志上栽过一次跟头，我们实验室做的关于RLKs参与植物抗逆的研究，投稿 elife 不到二周拒稿，最终文章被另一个高 IF 杂志 molecular cell 接收。
个人感觉说 elife 投稿容易的纯粹是扯淡！在生物学期刊里，molecular cell 的投稿难度相当大，至少远远难于 nature communications 、cell research 之流，而从我们实验室投稿经历来看， elife 投稿难度高于 molecular cell ，因此不难推测出 elife 投稿难度，绝对远远难于 nature communications 、cell research 之流。

664 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1198682, encodeId=69a31198682af, content=投稿命中率:5.0 偏重的研究方向：cell biology;微生物 经验分享：以后IF这种评价标准意义不大了，像elife这种完全不会主动去操作影响因子的杂志在中国认可度一定会越来越高，随便给大家推荐一个网站 https://www.resurchify.com/ranking 去这里面查杂志的好坏参考价值远比看IF来的靠谱，比如国产神刊之一的STTT排名是357，IF同样是8分的CDD排名是922，10分神刊JECCR排名是749，而elife排名是219, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=558, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f4e1713538, createdName=alexib, createdTime=Wed Mar 02 12:30:46 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2203519, encodeId=83a2220351957, content=偏重的研究方向：乳腺癌 经验分享： Stage Start Date Under editorial assessment 7th May 24 Initial quality checks complete 7th May 24 Staff checks pending 4th May 24 Manuscript submitted 4th May 24 Submission incomplete 3rd May 24 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Wed May 08 19:51:51 CST 2024, time=2024-05-08, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=580680, encodeId=1968580680ed, content=请问这个杂志拒稿快么？临近毕业还是想试一下高分，怕耽误太久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16365175013, createdName=146e4e40m72暂无昵称, createdTime=Fri Nov 29 00:00:00 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191264, encodeId=91d5119126433, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：Biomarker 经验分享：目前杂志只接受预印本。如果初审通过，必须先在预印本发表。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d03856469, createdName=bigOne, createdTime=Tue Feb 08 23:15:05 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861997, encodeId=706d86199e5b, content=审稿速度:1.0 经验分享：国际顶级期刊，审稿专家和编辑都非常严谨敬业，投稿难度挺大的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ce15414064, createdName=ms4608271349787965, createdTime=Tue Jun 16 23:01:04 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555417, encodeId=a3d255541e2e, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：个人感觉 elife 这个杂志投稿难度相当大，我曾经在这个杂志上栽过一次跟头，我们实验室做的关于RLKs参与植物抗逆的研究，投稿 elife 不到二周拒稿，最终文章被另一个高 IF 杂志 molecular cell 接收。 个人感觉说 elife 投稿容易的纯粹是扯淡！在生物学期刊里，molecular cell 的投稿难度相当大，至少远远难于 nature communications 、cell research 之流，而从我们实验室投稿经历来看， elife 投稿难度高于 molecular cell ，因此不难推测出 elife 投稿难度，绝对远远难于 nature communications 、cell research 之流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=664, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb651930132, createdName=storyhare, createdTime=Thu Apr 26 10:39:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2208556, encodeId=da172208556d8, content=偏重的研究方向：基础研究;口腔;生信 经验分享：请问投稿过程中under pending review阶段，稿件可以要求撤回修改吗，手稿提交出现错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:13:27 CST 2024, time=16小时前, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2203680, encodeId=ee3f22036805a, content=5月3号投出去，不知道编辑手里要多久，头大。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Thu May 09 15:15:33 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=575383, encodeId=adde5e538303, content=2019年8月15日投的稿，已经12天了，状态还是subbmitted，有没有大神遇到到这种情况，不是说elife审稿速度快吗？好着急啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58425127264, createdName=小高兴, createdTime=Mon Aug 26 22:49:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240235, encodeId=42021240235a0, content=2022未来科学奖的李文辉发的就是这个，这个杂志基本可以看成是open acess的PNAS，水平和投稿难度和PNAS基本差不多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7b18287601, createdName=ms7000000077155394, createdTime=Mon Aug 22 09:37:49 CST 2022, time=2022-08-22, status=1, ipAttribution=)]

16小时前 ms5000001730669209 来自广东省

偏重的研究方向：基础研究;口腔;生信
经验分享：请问投稿过程中under pending review阶段，稿件可以要求撤回修改吗，手稿提交出现错误

0 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1198682, encodeId=69a31198682af, content=投稿命中率:5.0 偏重的研究方向：cell biology;微生物 经验分享：以后IF这种评价标准意义不大了，像elife这种完全不会主动去操作影响因子的杂志在中国认可度一定会越来越高，随便给大家推荐一个网站 https://www.resurchify.com/ranking 去这里面查杂志的好坏参考价值远比看IF来的靠谱，比如国产神刊之一的STTT排名是357，IF同样是8分的CDD排名是922，10分神刊JECCR排名是749，而elife排名是219, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=558, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f4e1713538, createdName=alexib, createdTime=Wed Mar 02 12:30:46 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2203519, encodeId=83a2220351957, content=偏重的研究方向：乳腺癌 经验分享： Stage Start Date Under editorial assessment 7th May 24 Initial quality checks complete 7th May 24 Staff checks pending 4th May 24 Manuscript submitted 4th May 24 Submission incomplete 3rd May 24 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Wed May 08 19:51:51 CST 2024, time=2024-05-08, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=580680, encodeId=1968580680ed, content=请问这个杂志拒稿快么？临近毕业还是想试一下高分，怕耽误太久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16365175013, createdName=146e4e40m72暂无昵称, createdTime=Fri Nov 29 00:00:00 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191264, encodeId=91d5119126433, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：Biomarker 经验分享：目前杂志只接受预印本。如果初审通过，必须先在预印本发表。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d03856469, createdName=bigOne, createdTime=Tue Feb 08 23:15:05 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861997, encodeId=706d86199e5b, content=审稿速度:1.0 经验分享：国际顶级期刊，审稿专家和编辑都非常严谨敬业，投稿难度挺大的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ce15414064, createdName=ms4608271349787965, createdTime=Tue Jun 16 23:01:04 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555417, encodeId=a3d255541e2e, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：个人感觉 elife 这个杂志投稿难度相当大，我曾经在这个杂志上栽过一次跟头，我们实验室做的关于RLKs参与植物抗逆的研究，投稿 elife 不到二周拒稿，最终文章被另一个高 IF 杂志 molecular cell 接收。 个人感觉说 elife 投稿容易的纯粹是扯淡！在生物学期刊里，molecular cell 的投稿难度相当大，至少远远难于 nature communications 、cell research 之流，而从我们实验室投稿经历来看， elife 投稿难度高于 molecular cell ，因此不难推测出 elife 投稿难度，绝对远远难于 nature communications 、cell research 之流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=664, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb651930132, createdName=storyhare, createdTime=Thu Apr 26 10:39:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2208556, encodeId=da172208556d8, content=偏重的研究方向：基础研究;口腔;生信 经验分享：请问投稿过程中under pending review阶段，稿件可以要求撤回修改吗，手稿提交出现错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:13:27 CST 2024, time=16小时前, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2203680, encodeId=ee3f22036805a, content=5月3号投出去，不知道编辑手里要多久，头大。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Thu May 09 15:15:33 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=575383, encodeId=adde5e538303, content=2019年8月15日投的稿，已经12天了，状态还是subbmitted，有没有大神遇到到这种情况，不是说elife审稿速度快吗？好着急啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58425127264, createdName=小高兴, createdTime=Mon Aug 26 22:49:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240235, encodeId=42021240235a0, content=2022未来科学奖的李文辉发的就是这个，这个杂志基本可以看成是open acess的PNAS，水平和投稿难度和PNAS基本差不多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7b18287601, createdName=ms7000000077155394, createdTime=Mon Aug 22 09:37:49 CST 2022, time=2022-08-22, status=1, ipAttribution=)]

2024-05-09 darktempler 来自江苏省

5月3号投出去，不知道编辑手里要多久，头大。。。

7 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1198682, encodeId=69a31198682af, content=投稿命中率:5.0 偏重的研究方向：cell biology;微生物 经验分享：以后IF这种评价标准意义不大了，像elife这种完全不会主动去操作影响因子的杂志在中国认可度一定会越来越高，随便给大家推荐一个网站 https://www.resurchify.com/ranking 去这里面查杂志的好坏参考价值远比看IF来的靠谱，比如国产神刊之一的STTT排名是357，IF同样是8分的CDD排名是922，10分神刊JECCR排名是749，而elife排名是219, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=558, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f4e1713538, createdName=alexib, createdTime=Wed Mar 02 12:30:46 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2203519, encodeId=83a2220351957, content=偏重的研究方向：乳腺癌 经验分享： Stage Start Date Under editorial assessment 7th May 24 Initial quality checks complete 7th May 24 Staff checks pending 4th May 24 Manuscript submitted 4th May 24 Submission incomplete 3rd May 24 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Wed May 08 19:51:51 CST 2024, time=2024-05-08, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=580680, encodeId=1968580680ed, content=请问这个杂志拒稿快么？临近毕业还是想试一下高分，怕耽误太久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16365175013, createdName=146e4e40m72暂无昵称, createdTime=Fri Nov 29 00:00:00 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191264, encodeId=91d5119126433, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：Biomarker 经验分享：目前杂志只接受预印本。如果初审通过，必须先在预印本发表。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d03856469, createdName=bigOne, createdTime=Tue Feb 08 23:15:05 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861997, encodeId=706d86199e5b, content=审稿速度:1.0 经验分享：国际顶级期刊，审稿专家和编辑都非常严谨敬业，投稿难度挺大的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ce15414064, createdName=ms4608271349787965, createdTime=Tue Jun 16 23:01:04 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555417, encodeId=a3d255541e2e, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：个人感觉 elife 这个杂志投稿难度相当大，我曾经在这个杂志上栽过一次跟头，我们实验室做的关于RLKs参与植物抗逆的研究，投稿 elife 不到二周拒稿，最终文章被另一个高 IF 杂志 molecular cell 接收。 个人感觉说 elife 投稿容易的纯粹是扯淡！在生物学期刊里，molecular cell 的投稿难度相当大，至少远远难于 nature communications 、cell research 之流，而从我们实验室投稿经历来看， elife 投稿难度高于 molecular cell ，因此不难推测出 elife 投稿难度，绝对远远难于 nature communications 、cell research 之流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=664, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb651930132, createdName=storyhare, createdTime=Thu Apr 26 10:39:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2208556, encodeId=da172208556d8, content=偏重的研究方向：基础研究;口腔;生信 经验分享：请问投稿过程中under pending review阶段，稿件可以要求撤回修改吗，手稿提交出现错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:13:27 CST 2024, time=16小时前, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2203680, encodeId=ee3f22036805a, content=5月3号投出去，不知道编辑手里要多久，头大。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Thu May 09 15:15:33 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=575383, encodeId=adde5e538303, content=2019年8月15日投的稿，已经12天了，状态还是subbmitted，有没有大神遇到到这种情况，不是说elife审稿速度快吗？好着急啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58425127264, createdName=小高兴, createdTime=Mon Aug 26 22:49:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240235, encodeId=42021240235a0, content=2022未来科学奖的李文辉发的就是这个，这个杂志基本可以看成是open acess的PNAS，水平和投稿难度和PNAS基本差不多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7b18287601, createdName=ms7000000077155394, createdTime=Mon Aug 22 09:37:49 CST 2022, time=2022-08-22, status=1, ipAttribution=)]

2019-08-26 小高兴

2019年8月15日投的稿，已经12天了，状态还是subbmitted，有没有大神遇到到这种情况，不是说elife审稿速度快吗？好着急啊。

186 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1198682, encodeId=69a31198682af, content=投稿命中率:5.0 偏重的研究方向：cell biology;微生物 经验分享：以后IF这种评价标准意义不大了，像elife这种完全不会主动去操作影响因子的杂志在中国认可度一定会越来越高，随便给大家推荐一个网站 https://www.resurchify.com/ranking 去这里面查杂志的好坏参考价值远比看IF来的靠谱，比如国产神刊之一的STTT排名是357，IF同样是8分的CDD排名是922，10分神刊JECCR排名是749，而elife排名是219, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=558, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f4e1713538, createdName=alexib, createdTime=Wed Mar 02 12:30:46 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2203519, encodeId=83a2220351957, content=偏重的研究方向：乳腺癌 经验分享： Stage Start Date Under editorial assessment 7th May 24 Initial quality checks complete 7th May 24 Staff checks pending 4th May 24 Manuscript submitted 4th May 24 Submission incomplete 3rd May 24 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Wed May 08 19:51:51 CST 2024, time=2024-05-08, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=580680, encodeId=1968580680ed, content=请问这个杂志拒稿快么？临近毕业还是想试一下高分，怕耽误太久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16365175013, createdName=146e4e40m72暂无昵称, createdTime=Fri Nov 29 00:00:00 CST 2019, time=2019-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191264, encodeId=91d5119126433, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：Biomarker 经验分享：目前杂志只接受预印本。如果初审通过，必须先在预印本发表。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d03856469, createdName=bigOne, createdTime=Tue Feb 08 23:15:05 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861997, encodeId=706d86199e5b, content=审稿速度:1.0 经验分享：国际顶级期刊，审稿专家和编辑都非常严谨敬业，投稿难度挺大的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=436, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ce15414064, createdName=ms4608271349787965, createdTime=Tue Jun 16 23:01:04 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555417, encodeId=a3d255541e2e, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：个人感觉 elife 这个杂志投稿难度相当大，我曾经在这个杂志上栽过一次跟头，我们实验室做的关于RLKs参与植物抗逆的研究，投稿 elife 不到二周拒稿，最终文章被另一个高 IF 杂志 molecular cell 接收。 个人感觉说 elife 投稿容易的纯粹是扯淡！在生物学期刊里，molecular cell 的投稿难度相当大，至少远远难于 nature communications 、cell research 之流，而从我们实验室投稿经历来看， elife 投稿难度高于 molecular cell ，因此不难推测出 elife 投稿难度，绝对远远难于 nature communications 、cell research 之流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=664, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb651930132, createdName=storyhare, createdTime=Thu Apr 26 10:39:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2208556, encodeId=da172208556d8, content=偏重的研究方向：基础研究;口腔;生信 经验分享：请问投稿过程中under pending review阶段，稿件可以要求撤回修改吗，手稿提交出现错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:13:27 CST 2024, time=16小时前, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2203680, encodeId=ee3f22036805a, content=5月3号投出去，不知道编辑手里要多久，头大。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Thu May 09 15:15:33 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=575383, encodeId=adde5e538303, content=2019年8月15日投的稿，已经12天了，状态还是subbmitted，有没有大神遇到到这种情况，不是说elife审稿速度快吗？好着急啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58425127264, createdName=小高兴, createdTime=Mon Aug 26 22:49:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240235, encodeId=42021240235a0, content=2022未来科学奖的李文辉发的就是这个，这个杂志基本可以看成是open acess的PNAS，水平和投稿难度和PNAS基本差不多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7b18287601, createdName=ms7000000077155394, createdTime=Mon Aug 22 09:37:49 CST 2022, time=2022-08-22, status=1, ipAttribution=)]

2022-08-22 ms7000000077155394

2022未来科学奖的李文辉发的就是这个，这个杂志基本可以看成是open acess的PNAS，水平和投稿难度和PNAS基本差不多

144 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务